Quiet CinCor Pharma makes some noise with $143M, new trial plans for blood pressure drug

CinCor Pharma has been fairly quiet since emerging in the hypertension space a couple of years ago with a former Roche program in tow. Not anymore.

On Tuesday, the Cincinnati-based biotech unwrapped a $143 million Series B round led by General Atlantic. And judging by the size of the raise and the syndicate of blue-chip investors, it seems likely that CEO Marc de Garidel has the S-1 papers ready to go.